Holen Sie sich die Stockscreener-App
60.27
0.18%
0.05
Handel nachbörslich:
60.36
0.09
+0.15%
Schlusskurs vom Vortag:
$60.22
Offen:
$60.36
24-Stunden-Volumen:
554.07K
Relative Volume:
0.37
Marktkapitalisierung:
$6.47B
Einnahmen:
$769.10M
Nettoeinkommen (Verlust:
$46.67M
KGV:
172.20
EPS:
0.35
Netto-Cashflow:
$119.79M
1W Leistung:
+3.62%
1M Leistung:
+30.98%
6M Leistung:
-24.40%
1J Leistung:
-23.33%
1-Tages-Spanne:
$59.03
$60.80
1-Wochen-Bereich:
$57.10
$60.95
52-Wochen-Spanne:
$28.66
$91.00
Corcept Therapeutics Inc Stock (CORT) Company Profile
Firmenname
Corcept Therapeutics Inc
Sektor
Branche
Telefon
650.688.8803
Adresse
101 REDWOOD SHORES PARKWAY, REDWOOD CITY
Compare CORT vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CORT
Corcept Therapeutics Inc
|
60.27 | 6.46B | 769.10M | 46.67M | 119.79M | 0.35 |
VRTX
Vertex Pharmaceuticals Inc
|
435.92 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.42 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.61 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Corcept Therapeutics Inc Stock (CORT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-26 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2025-12-31 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
| 2025-12-16 | Eingeleitet | UBS | Neutral |
| 2025-11-18 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-11-06 | Hochstufung | Truist | Hold → Buy |
| 2023-04-11 | Eingeleitet | SVB Securities | Market Perform |
| 2023-04-04 | Eingeleitet | Piper Sandler | Overweight |
| 2023-02-15 | Herabstufung | Jefferies | Buy → Hold |
| 2022-08-01 | Herabstufung | Truist | Buy → Hold |
| 2022-07-27 | Hochstufung | Jefferies | Hold → Buy |
| 2022-06-27 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-02-02 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-01-28 | Eingeleitet | Truist | Buy |
| 2020-08-05 | Herabstufung | Jefferies | Buy → Hold |
| 2019-09-24 | Eingeleitet | Jefferies | Buy |
| 2019-09-06 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-02-04 | Herabstufung | B. Riley FBR | Buy → Neutral |
| 2018-08-10 | Bestätigt | Stifel | Hold |
| 2018-05-31 | Herabstufung | Stifel | Buy → Hold |
| 2018-03-09 | Eingeleitet | B. Riley FBR, Inc. | Buy |
| 2017-08-31 | Eingeleitet | Stifel | Buy |
| 2017-02-02 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2015-04-21 | Eingeleitet | FBR Capital | Outperform |
| 2014-01-13 | Herabstufung | Stifel | Buy → Hold |
| 2013-08-09 | Herabstufung | Janney | Buy → Neutral |
| 2013-08-09 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2012-02-21 | Bestätigt | JMP Securities | Mkt Outperform |
| 2010-01-06 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
| 2008-07-17 | Eingeleitet | Rodman & Renshaw | Mkt Outperform |
| 2007-06-21 | Hochstufung | Punk, Ziegel & Co | Mkt Perform → Accumulate |
Alle ansehen
Corcept Therapeutics Inc Aktie (CORT) Neueste Nachrichten
Corcept Therapeutics climbs on UBS upgrade - MSN
CORT Stock Price, Quote & Chart | CORCEPT THERAPEUTICS INC (NASDAQ:CORT) - ChartMill
Affiliate of CORT (NASDAQ: CORT) files Form 144 to offer 5,000 shares - Stock Titan
Wall Street Analysts Believe Corcept (CORT) Could Rally 43.32%: Here's is How to Trade - Yahoo Finance UK
Corcept Therapeutics Inc. (CORT) Stock Analysis: Exploring a 40.15% Potential Upside for Biotech Investors - DirectorsTalk Interviews
Corcept (CORT) chief business officer reports 7,300-share gift of common stock - Stock Titan
CORT Stock Chart | CORCEPT THERAPEUTICS INC (NASDAQ:CORT) - ChartMill
UBS upgrades Corcept Therapeutics (CORT) - MSN
Corcept Therapeutics (CORT) Receives Upgrade, Stock Surges Over 7% - GuruFocus
Corcept Therapeutics Shares Rise After UBS Upgrade - Moomoo
UBS Upgrades Corcept Therapeutics(CORT.US) to Buy Rating, Cuts Target Price to $72 - Moomoo
Corcept Therapeutics (CORT) Stock Analysis: Unveiling a 40% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
CORT Q1 earnings match estimates, revenues miss, 2026 outlook raised - MSN
Vanguard Group Inc. Has $330.42 Million Holdings in Corcept Therapeutics Incorporated $CORT - MarketBeat
Why Corcept Therapeutics Stock Is Sinking Now - TipRanks
CORT IMPORTANT DEADLINE: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Corcept Therapeutics Incorporated Investors with Losses in Excess of $100K to Secure Counsel Before Important April 21 Deadline in Securities Class ActionCORT - TMX Newsfile
Corcept (CORT) CDO sells 20K shares under 10b5-1 plan - Stock Titan
CORT FINAL DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Corcept Therapeutics Incorporated Investors with Losses in Excess of $100K to Secure Counsel Before Important April 21 Deadline in Securities Class ActionCORT - TMX Newsfile
Corcept Therapeutics (CORT) Is Up 11.9% After Q1 Loss, Higher 2026 Outlook And ALS DataHas The Bull Case Changed? - Yahoo Finance
Corcept (CORT) Q1 2025 Earnings Transcript - AOL.com
Corcept Must Face Most Teva Mifepristone Antitrust Claims - Law360
Corcept Therapeutics IncorporatedCommon Stock (NQ: CORT - FinancialContent
How many employees work at Corcept Therapeutics? - Revelio Labs
Teva's US exclusive-dealing claims survive Corcept's move to dismiss - MLex
Corcept (NASDAQ: CORT) CEO sells 40K shares under 10b5-1 plan - Stock Titan
Corcept Therapeutics (NASDAQ: CORT) affiliate plans sale of 20,000 shares via Stifel - Stock Titan
Corcept Therapeutics Incorporated (NASDAQ:CORT) Q1 2026 Earnings Call Transcript - Insider Monkey
CORT Q1 Deep Dive: Early Lifyorli Launch and Endocrinology Momentum Offset Margin Pressures - Yahoo Finance
Corcept (CORT) Q1 2026 Earnings Transcript - AOL.com
Corcept Therapeutics Is Maintained at Buy by HC Wainwright & Co. - Moomoo
CCORF Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Maintains Target Price $110 - Moomoo
Corcept (CORT) Q2 2025 Earnings Transcript - AOL.com
Corcept (CORT) Q4 2025 Earnings Transcript - AOL.com
CORT Maintained by HC Wainwright & Co. -- Price Target Raised to $75 - GuruFocus
CORT DEADLINE: ROSEN, A LEADING AND TOP RANKED LAW FIRM, Encourages Corcept Therapeutics Incorporated Investors with Losses in Excess of $100K to Secure Counsel Before Important April 21 Deadline in Securities Class ActionCORT - TMX Newsfile
Corcept Therapeutics Inc. (CORT) Stock Analysis: A 36.91% Upside Potential In Biotech - DirectorsTalk Interviews
MSN Money - MSN
symbol__ Stock Quote Price and Forecast - CNN
Corcept (CORT) Upgraded After Key Regulatory Approval for Lifyorli - Yahoo Finance
Corcept Therapeutics Shakes Up Nasdaq Index Fund Radar - Kalkine Media
CORT Maintained by Piper Sandler -- Price Target Raised to $88 - GuruFocus
Corcept Therapeutics Guides Higher on Lifyorli-Fueled Revenue Growth - The Globe and Mail
Corcept Therapeutics Is Maintained at Overweight by Piper Sandler - Moomoo
Corcept Therapeutics (NASDAQ:CORT) Stock Price Up 7.9%Time to Buy? - MarketBeat
Corcept Therapeutics (CORT) insider notifies sale of 40,000 shares via Stifel - Stock Titan
CORT Q1 Earnings Match Estimates, Revenues Miss, 2026 Outlook Raised - The Globe and Mail
Corcept Therapeutics Pivotal Study Shows 87% Lower Death Risk - Benzinga
Corcept Therapeutics Incorporated Q1 2026 Earnings Call Summary - Yahoo Finance
Corcept Therapeutics Inc (CORT) Q1 2026 Earnings Call Highlights - GuruFocus
Finanzdaten der Corcept Therapeutics Inc-Aktie (CORT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Corcept Therapeutics Inc-Aktie (CORT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Guyer William | Chief Development Officer |
May 05 '26 |
Option Exercise |
21.65 |
20,000 |
433,000 |
22,231 |
| Guyer William | Chief Development Officer |
May 05 '26 |
Sale |
51.83 |
20,000 |
1,036,600 |
2,231 |
| BELANOFF JOSEPH K | Chief Executive Officer |
May 01 '26 |
Sale |
50.10 |
40,000 |
2,003,860 |
2,878,326 |
1.49%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):